drugset
drugset / Trial / NCT04788017

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

NCT04788017 ↗

Phase 1 Completed 24 enrolled Shanghai Ark Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindHealth-services research

Summary

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.

Timeline

Start
2021-03-24
Primary completion
2021-06-14
Completion
2021-07-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ziresovir Small molecule 300 mg Oral
Comparator Ziresovir Small molecule 600 mg Oral
Comparator Ziresovir Small molecule 900 mg Oral

Indications

No indication recorded.